Drug Shadam authorized to delay cognitive deficit in patients with Alzheimer’s in the European Union
According to information provided by the European Brain Council at the beginning of 2025, there were seven million people in Europe, and by 2030, the number is expected to double by 2030.
GSO pictures
The European Commission has authorized Lekebi to use a medicine shadam for cognitive deficit treatment on Wednesday, early stages Alzheimer’s diseaseThis type of first drug shadam is allowed in the European Union (EU).
In a statement, community executive drug declares the authority of Shadam “In restricted situations“The”, that “Medicine Shadam is for use in people who do not have a copy of one or Apoi 4 gene and they have beta amyloid plates in the brain. “
The Apoi 4 gene is an apoi genetic variation, which is responsible for representing the body in the production of Apolloprotein (protein containing lipoproteins). The Apoi 4 variant is associated with the development of Alzheimer’s disease, usually from 65 years.
The disease is classified by gradual decline in cognitive abilities, Including memory loss.
Beta amyloid plaques are characteristic of ‘asphixed’ communication between Alzheimer’s disease and neurons.
The European Commission’s authorized positive assessment for the use of LecmI European Agency of Medical (EMA)“It was over The advantages of this Drug Shadam overlap with dangers ”But in the “patient population” and “risk minimizing actions” only with actions.
According to information provided by the European Brain Council at the beginning of 2025, there were seven million people in Europe, and by 2030, the number is expected to double by 2030.
